ClinicalTrials.gg
RecruitingNCT07214753ATHENAUpdated Sep 18, 2026

A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

An observational study in Severe Eosinophilic Asthma, sponsored by AstraZeneca. Recruiting at 28 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
335
Ages
18 Years and older
Sex
All
01

Study summary

This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.

Read the detailed description

The ATHENA study aims to expand real-world evidence on benralizumab role in clinical practice, specifically evaluating its effectiveness in achieving clinical remission (complete and partial), as defined by SANI. Additionally, given the growing importance of biomarkers in asthma research, this study seeks to further investigate benralizumab immunological effects, potentially contributing to a deeper understanding of asthma pathophysiology and addressing existing knowledge conundrum. Additionally, the study will consolidate long-term safety data.

02

Conditions studied

  • Severe Eosinophilic Asthma
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Severe eosiniphilic asthma patients treated with benralizumab as per clinical practices

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma.
  • Benralizumab has been prescribed according to the approved label and local reimbursement criteria
  • Provision of signed Form (ICF) prior to any study-related activities
  • Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study).

Exclusion criteria

Exclusion Criteria:

  • Benralizumab treatment within the 12 months prior to study enrollment and up to 8 days before enrollment
  • Previous participation (in the 12 months before enrollment), current participation or plan to participate within the follow up period to any other clinical trial.
  • to benralizumab as per current Summary of Product Characteristics (SmPC).
  • Pregnant or lactating women.
  • patients with any clinical condition that may interfere with the subject's ability to cooperate and comply with the study procedures based on the Investigator's judgement.
  • Previous or concomitant use of omalizumab, reslizumab, dupilumab, tezepelumab or mepolizumab without as per clinical practice
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
335 participants (estimated)
Patient registry
No

Interventions

  • Biologicalbenralizumab

    30mg s.c. as per SmPC

    Also known as: Fasenra

06

What researchers measure

Primary outcomes

  1. Number and percentage of patients achieving clinical remission, partial and complete, as per SANI Definition

    Number and percentage of patient who met the 4 remission criteria (complete or partial) at 12 months and maintained up to 24months

    Time frame: 24 months

Secondary outcomes

  1. Number and percentage of patients achieving the criteria for clinical remission

    Number and percentage of patient with the criteria for complete or partial remission according to the following criteria: No need to use OCS; Absence of asthma symptoms (ACT score from 20/25 to 25/25); Absence of asthma exacerbations; Stable lung function (FEV1 decline of no more than 100 mL).

    Time frame: 3, 6, 12 and 24 months

  2. Rate of any and SA exacerbations

    annualized exacerbations rate

    Time frame: 3, 6, 12 and 24 months

  3. Mean change in Asthma Control Test (ACT) score

    mean (SD) changes (min - max) overtime in ACT score

    Time frame: 1, 3, 6, 12 and 24 months vs baseline

  4. Mean changes in Asthma Control Questionnaire (ACQ) score

    mean (SD) changes (min - max) overtime in ACQ score

    Time frame: 1, 3, 6, 12 and 24 months vs baseline

  5. Mean change in FEV1 - pre-BD

    mean (SD) changes in FEV1 (L) overtime

    Time frame: 3, 6, 12 and 24 vs baseline

  6. Mean changes in FEV1 - post-BD

    mean (SD) changes in FEV1 (L) post-BD

    Time frame: 3, 6, 12 and 24 months vs baseline

  7. Mean changes in FEV1 % predicted - pre-BD

    mean (SD) changes in FEV1 % predicted pre-BD

    Time frame: 3, 6, 12 and 24 months vs baseline

  8. Mean changes in FEV1 % predicted - post-BD

    mean (SD) changes in FEV1 % predicted post-BD

    Time frame: 3, 6, 12 and 24 months vs baseline

  9. Mean changes in FVC pre-BD

    mean (SD) changes in FVC (L) pre-BD

    Time frame: 3, 6, 12 and 24 months vs baseline

  10. Mean changes in FVC post-BD

    mean (SD) changes in FVC (L) post-BD

    Time frame: 3, 6, 12 and 24 months vs baseline

  11. Mean changes in pre-BD FEV1/FVC

    mean (SD) changes in pre-BD FEV1/FVC (ratio)

    Time frame: 3, 6, 12 and 24 months vs baseline

  12. Mean changes in pre-BD FEF 25-75

    mean (SD) changes in pre\_BD FEF25-75 (L/sec)

    Time frame: 3, 6, 12 and 24 months vs baseline

  13. Mean changes in post-BD FEF 25-75

    mean (SD) changes in post-BD FEF25-75 (L/sec)

    Time frame: 3, 6, 12 and 24 months vs baseline

  14. Mean changes in post-BD FEV1/FVC

    mean (SD) changes in post-BD FEV1/FVC (ratio)

    Time frame: 3, 6, 12 and 24 months vs baseline

  15. Change in inhaled maintenance therapy and inhaled corticosteroid (ICS/LABA/LAMA, ICS/LABA) use and dosage

    Change in inhaled maintenance therapy and inhaled corticosteroid (ICS/LABA/LAMA, ICS/LABA) use and dosage after benralizumab treatment

    Time frame: 3, 6, 12 and 24 months

  16. Change in mOCS use and daily dose

    Change in mOCS use and daily dose after benralizumab administartion

    Time frame: 3, 6, 12 and 24 months

07

Study locations

12 of 28 sites recruiting
  • Research Site
    Salerno, Battipaglia 84031, Italy
    Not yet recruiting
  • Research Site
    Padova, Cittadella 35013, Italy
    Not yet recruiting
  • Research Site
    Teramo, Giulianova 64021, Italy
    Recruiting
  • Research Site
    Treviso, Montebelluna 31044, Italy
    Recruiting
  • Research Site
    Varese, Tradate 21049, Italy
    Recruiting
  • Research Site
    Bari, 70120, Italy
    Recruiting
  • Research Site
    Bergamo, 24127, Italy
    Not yet recruiting
  • Research Site
    Bologna, 40138, Italy
    Recruiting
  • Research Site
    Bologna, 40139, Italy
    Not yet recruiting
  • Research Site
    Brescia, 25123, Italy
    Not yet recruiting
  • Research Site
    Catania, 95123, Italy
    Not yet recruiting
  • Research Site
    Catanzaro, 88100, Italy
    Recruiting
  • Research Site
    Florence, 50134, Italy
    Not yet recruiting
  • Research Site
    Foggia, 71122, Italy
    Not yet recruiting
  • Research Site
    Messina, 98124, Italy
    Not yet recruiting
  • Research Site
    Milan, 20142, Italy
    Recruiting
  • Research Site
    Modena, 41125, Italy
    Recruiting
  • Research Site
    Naples, 80131, Italy
    Recruiting
  • Research Site
    Naples, 80131, Italy
    Not yet recruiting
  • Research Site
    Padova, 35128, Italy
    Not yet recruiting
  • Research Site
    Palermo, 90127, Italy
    Recruiting
  • Research Site
    Pavia, 27100, Italy
    Not yet recruiting
  • Research Site
    Roma, 00152, Italy
    Not yet recruiting
  • Research Site
    Roma, 00189, Italy
    Recruiting
  • Research Site
    Sassari, 07100, Italy
    Not yet recruiting
  • Research Site
    Siena, 53100, Italy
    Not yet recruiting
  • Research Site
    Torino, 10128, Italy
    Recruiting
  • Research Site
    Verona, 37134, Italy
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2025
First posted
Oct 9, 2025
StartActual
Dec 20, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07214753
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Dec 20, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 18, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion